Key result
Blockade of the renin-angiotensin-aldosterone system has been established over a 25-year period as the cornerstone of therapy for patients with systolic heart failure.
This review provides a historical overview of the discovery and overwhelming evidence supporting RAAS blockade as the cornerstone of therapy for systolic heart failure.
Reinforces RAAS blockade as standard in systolic HF; leaves open optimization with newer agents.
We will shortly celebrate the 25th anniversary of the publication of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS), a clinical trial which revolutionized the treatment of heart failure and highlighted the importance of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of heart failure (Figure 1). In this article I will give a brief, historical overview of this exciting quarter-century of discovery related to the RAAS. My focus is on the treatment of heart failure in patients with a low left ventricular ejection fraction.
No takes yet. Share an insight, caveat, or question.
John J.V. McMurray (2011) conducted a review in Systolic Heart Failure. Renin-Angiotensin-Aldosterone System (RAAS) blockade was evaluated. Blockade of the renin-angiotensin-aldosterone system has been established over a 25-year period as the cornerstone of therapy for patients with systolic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: